Stock CLDI CALI BIOTPAR
Add to a list
To use this feature you must be a member
Log inSign up

News CALI BIOTPAR

Equities

CLDI

US3207031010

Market Closed - Nyse
Other stock markets
 01:40:00 16/07/2024 am IST 		5-day change 1st Jan Change
1.75 USD +10.55% Intraday chart for CALI BIOTPAR +7.96% -88.41%
08/07 Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin CI
05/07 Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin
CI
Calidi to Effect Reverse Stock Split
AQ
Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split
MT
Calidi to Effect Reverse Stock Split
BU
Calidi Biotherapeutics, Inc. announced that it has received $0.6 million in funding
CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $0.6 million in funding
CI
Ladenburg Thalmann Initiates Calidi Biotherapeutics at Buy
MT
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
BU
Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors
CI
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
BU
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care
MT
Calidi Biotherapeutics Signs Virotherapy Deal With Siga Technologies -- Calidi Shares Surge Pre-Bell
MT
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
BU
Calidi Biotherapeutics Collaborates with Siga Technologies to Advance Calidi?S Revolutionary Rtnova Virotherapy for Lung Cancer and Metastatic Solid Tumors
CI
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
BU
Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting
CI
 Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BU
Calidi Biotherapeutics, Inc. Announces Resignation of David Lapre as Director
CI
Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. News CALI BIOTPAR